We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Neurocrine Biosciences Inc | NASDAQ:NBIX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.15 | 0.84% | 137.85 | 137.50 | 137.98 | 138.685 | 137.51 | 138.00 | 11,081 | 14:36:04 |
From May 2023 to May 2024
By Brenda León
Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal involuntary movement disorder associated with Huntington's disease.
The San Diego-based biopharmaceutical company said the FDA approval is supported by data from two clinical studies conducted in collaboration with the Huntington Study Group.
Huntington's disease is a hereditary progressive neurodegenerative disorder in which the loss of certain neurons within the brain causes motor, cognitive and psychiatric symptoms.
Most people with the disease experience chorea, which is characterized by irregular and unpredictable movements. Chorea can affect various parts of the body and interfere with motor coordination, gait, swallowing and speech.
Huntington's disease affects an estimated 41,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease, Neurocrine Biosciences said.
Write to Brenda León at brenda.leon@wsj.com
(END) Dow Jones Newswires
August 18, 2023 17:18 ET (21:18 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Neurocrine Biosciences Chart |
1 Month Neurocrine Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
